

DEK::AFF2 Squamous Cell Carcinoma is a Deceptive Mimic of Inverted Sinonasal Papilloma: A Case Report

Karen Cybelle Sotalbo, Jonathan Rivera, Clarisse Anne Nuqui

Department of Laboratories, Philippine General Hospital

ABSTRACT

An elderly Filipino female presented with a 5-year enlarging left nasolacrimal mass initially diagnosed as Inverted Papilloma of the Lacrimal Sac. Repeat biopsy revealed a papillomatous neoplasm with thick and thin papillae, solid invaginating lobules, and anastomosing trabeculae of monomorphic squamotransitional cells, briskly infiltrated by neutrophils. Mucocytes, respiratory epithelium, and microcysts, typical of Inverting Sinonasal Papilloma, are absent. Immunohistochemistry, including a validated AFF2 IHC, confirmed the diagnosis of DEK::AFF2 sinonasal carcinoma. Awareness of this emerging entity is essential to prevent misdiagnosis and prompt surgical management.

Key words: DEK, AFF2, squamous cell carcinoma, case report, Philippines

ISSN 2507-8364 (Online)

Printed in the Philippines.

Copyright© 2026 by Sotalbo et al.

Received: 21 March 2026.

Accepted: 19 April 2026.

Published online first: 11 June 2026.

<https://doi.org/10.21141/PJP.2026.615>

Corresponding author: Jonathan P. Rivera, MD

E-mail: jonathanriveraMD@gmail.com

ORCID: <https://orcid.org/0000-0003-0268-4664>

INTRODUCTION

DEK::AFF2 sinonasal carcinoma is an emerging entity in the sinonasal tract and skull base classified as a subtype of Non-keratinizing Squamous Cell Carcinoma. However, it is likely an under-recognized neoplasm often misdiagnosed as a benign inverted sinonasal papilloma (ISP) due to its frequent papillomatous growth and strikingly bland monomorphic cytology.¹⁻⁵ Alternatively, due to its banal appearance, some cases of DEK::AFF2 sinonasal carcinoma have been previously classified as “low-grade papillary Schneiderian carcinoma.”²⁻⁶ A subset of cases may also display overt carcinomatous features similar to non-keratinizing squamous cell carcinoma or adenosquamous carcinoma of the sinonasal tract and skull base.^{2,3,5} The diagnosis is made upon evaluation of key histologic and immunophenotypic features followed by confirmatory molecular testing for the DEK::AFF2 fusion or a validated immunohistochemical (IHC) assay for the AFF2 protein, as a confirmatory surrogate.³ Increasing awareness is important as this tumor can have frequent local recurrences, occasional lymph node and distant metastases, and rare tumor-related deaths.^{3,5} Here, we report the first diagnosed case of DEK::AFF2 sinonasal carcinoma in an elderly Filipino patient.

CASE

A 76-year-old female presented with a 5-year history of an enlarging left nasolacrimal mass. The mass began at the medial aspect of the left eye, with associated tearing and discharge. Eye drops were initially prescribed but afforded no relief from symptoms. She then sought consultation from another institution, where she was diagnosed with Chronic Dacryocystitis and Nasolacrimal Duct Obstruction, and subsequently underwent laser dacryocystorhinostomy. The patient reported slight relief of symptoms. However, in the interim, there was a gradual enlargement of the mass with an increase in tearing and discharge. Two months before the consult, a biopsy was done in another institution, where she was diagnosed with papilloma of the lacrimal duct, inverted type. Antibiotics



were prescribed, but the mass continued to increase in size, now with a left nasal extension. The patient eventually sought a consultation at the outpatient department.

On physical examination, there was a 4.0 x 4.0 x 2.0 cm firm, non-tender, fixed nodular mass on the left maxilla involving the left orbit and medial canthus. There was noted tearing and crusting of the left eye. On rhinoscopy, there was a fleshy mass completely obstructing the left nasal cavity. The rest of the physical examination, family history, and previous medical history are unremarkable.

Imaging showed that the mass arose from the left lacrimal sac with extension to the pre- and post-septal cavity, abutting the medial rectus muscle. The mass also extends to the inferomedial aspect of the globe, left frontal sinus, left anterior ethmoid sinus, and left nasal cavity, indenting the turbinates, and occupying the left nasolacrimal sac and duct. Mild septal deviation is seen (Figure 1A). No intracranial extension was noted. The right frontal, ethmoid, and sphenoid sinuses, as well as the right nasal cavity, are uninvolved. A repeat biopsy was done and sent for histopathologic examination.

The tissue sample consists of several tan-brown fleshy fragments with an aggregate dimension of 3.5 cm. Histologic examination shows a papillomatous neoplasm forming thin and thick papillae, solid endophytic lobules, and anastomosing trabeculae of epithelial tumor cells (Figure 1B). The endophytic lobules comprise a solid proliferation of squamotransitional cells reminiscent of inverting sinonasal papilloma (Figure 1C). However, in contrast to inverting sinonasal papilloma, the neoplastic epithelium does not contain mucocytes, intermediate or respiratory-type epithelial cells, and microcysts that contain microabscesses. Instead, the polygonal tumor cells display striking monomorphism, ovoid vesicular nuclei, conspicuous nucleoli, and ample eosinophilic cytoplasm. An accompanying brisk peritumoral and intratumoral neutrophilic infiltrate is seen (Figure 1D). Due to the aforementioned histologic findings, immunohistochemical work-up using Pancytokeratin (AE1/AE3), p63, NUT, INI-1, and *AFF2* for the C-terminus were performed. The tumor showed strong and diffuse expression of pancytokeratin and p63 (Figure 1E), confirming an epithelial neoplasm with squamous differentiation, was negative for NUT (*image not included*), ruling out a NUT carcinoma, and had retained expression of INI-1 (*image not included*), excluding a SMARCB1-deficient sinonasal carcinoma. The tumor showed a strong diffuse nuclear expression of *AFF2* in all tumor cells (Figure 1F), confirming the diagnosis of *DEK::AFF2* sinonasal carcinoma. The patient underwent complete resection of the tumor, including the orbital contents.

DISCUSSION

Epidemiology/Incidence

Sinonasal carcinomas are rare (1/100,000 population) and aggressive tumors that represent 3-5% of all head and neck cancers. Investigation of publicly available RNA data sets of sinonasal papillomas and squamous cell carcinomas and review of recurrent sinonasal papillomas over a two-decade period have suggested *DEK::AFF2* sinonasal carci-

noma to occur in 4.7-10.7% of cases. A total of 49 cases has been published to date.¹⁻¹⁰ This is the first reported case of *DEK::AFF2* sinonasal carcinoma in the Philippines.

Clinicopathologic features, presentation, and anatomic involvement

DEK::AFF2 sinonasal carcinoma most frequently involves the nasal cavity. This is followed in decreasing order of frequency by the nasopharynx, skull base, paranasal sinuses, middle ear, orbit, temporal bone, and rarely, by the lacrimal sac, similar to the present case.^{3,5} Interestingly, a case of *DEK::AFF2*-rearranged carcinoma has been reported in the lung with broncho-centric growth and co-expression of p40 and TTF-1, suggesting a potential origin from the basal cells of the respiratory epithelium.⁷

Morphologic features, differential diagnosis, and ancillary work-up

The histologic features of *DEK::AFF2* sinonasal carcinoma usually fit into three distinct morphologic patterns, which may guide pathologists to its recognition. The Low-grade Papillary Schneiderian Carcinoma subtype is the most common. From its namesake, prior cases with this morphologic pattern were previously classified as “Low-grade Papillary Schneiderian Carcinomas” but were later found to harbor the defining *DEK::AFF2* fusion, resulting in their reclassification.^{2,6} In this subtype, the neoplastic epithelium forms endophytic lobules usually with rounded non-infiltrative contours and anastomosing trabeculae, resembling ISP, its closest differential. In contrast to ISP, the tumor usually displays a greater architectural complexity, with back-to-back invaginating lobules and trabeculae forming a maze-like or labyrinthine pattern. Furthermore, the cells are strikingly monomorphic and bland, without the usual admixture of squamous, mucocytes, and respiratory-type cells in the epithelium and abscess-containing microcysts, which are distinguishing features of ISP. Likewise, these cell components are required to be at least focally present in ISP with dysplasia or carcinoma-ex ISP. Conspicuous central acantholytic change in the lobules confers a dilapidated appearance, pseudopapillary pattern, or areas reminiscent of stellate reticulum, which could be mistaken for ameloblastic epithelium. Stromal neutrophilic infiltrates surround the lobules or infiltrate between tumor cells.^{2,3,6} Less commonly, *DEK::AFF2* sinonasal carcinoma may display an infiltrative pattern with varying but often limited squamous and/or glandular differentiation, corresponding to the non-keratinizing squamous cell carcinoma and adenosquamous carcinoma morphologic subtypes. When encountering these 2 morphologic subtypes, a wide range of differential diagnoses is considered. Briefly, cases of non-keratinizing squamous cell carcinoma subtype should be distinguished from 1) Virus-related (EBV or HPV) carcinomas; 2) Squamous cell carcinoma arising from ISP with an underlying EGFR-mutation; 3) poorly-differentiated malignant neoplasms with squamous phenotype to include NUT carcinoma, SWI/SNF-related carcinoma, and adamantinoma-like ewing sarcoma; and 4) Carcinogen-driven squamous cell carcinomas. Cases with adenosquamous carcinoma should be distinguished from HPV-multiphenotypic sinonasal carcinoma, adenosquamous carcinoma, and from mucoepidermoid carcinoma. Thus, work-up to variably consist of p40, p16,




Figure 1. Imaging and histopathologic findings of the case. (A) Imaging shows the tumor in the ethmoid sinus and left nasal cavity. It abuts the medial rectus muscle and displaces the left globe (*white arrow*). (B) Tumor fragments consist of papillae, solid endophytic lobules, and anastomosing thick trabeculae of tumor cells (H&E, 40x). (C) Solid endophytic lobules resemble those of inverting sinonasal papilloma but with greater cell crowding and solid growth (H&E, 100x). (D) Squamo-transitional tumor cells are monomorphic with ovoid vesicular nuclei and ample eosinophilic cytoplasm. Mucocytes, respiratory epithelium, and microcysts typical of ISP are not observed. Neutrophils surround the tumor cell clusters or infiltrate between tumor cells (H&E, 400x). (E) Tumor shows nuclear expression of p63 (IHC, 200x). (F) Tumor shows strong diffuse nuclear expression of *AFF2* in all cells (IHC, 200x).

NUT, INI-1, BRG1, CD99, and NKX2.2 IHCs, EBERish and HPVish, and/or molecular testing for *MAML2* gene rearrangement, will select cases requiring further *DEK::AFF2* fusion confirmatory testing.^{3,8,9}

Molecular testing and *AFF2* IHC

The diagnosis of *DEK::AFF2* carcinoma is based on the presence of the defining *DEK::AFF2* gene fusion. The *DEK::AFF2* fusion has been identified using whole-genome sequencing,¹⁰ whole transcriptome sequencing,² targeted RNA next-generation sequencing (NGS),^{1,11,12} and/or fluorescent in situ hybridization (FISH) using *DEK* dual fusion or break-apart probes.^{2,6,10,13,14} Furthermore, recognition of the breakpoints and fusion variants has led to the development of specific primers to identify the *DEK::AFF2* fusion via reverse transcription polymerase chain reaction (RT-PCR).⁶ More recently, studies on the differential *AFF2* protein expression in fusion-positive tumors have led to the development of an immunohistochemical assay targeting the C-terminus peptide of the *AFF2* protein.² An adequately validated *AFF2* IHC has demonstrated excellent sensitivity, specificity, positive predictive value, and negative predictive value as a surrogate marker for the *DEK::AFF2* fusion when at least 30% of tumor cells are observed to display moderate to strong nuclear expression.^{2,5,14,15} Thus, in resource-limited settings, RT-PCR or a rigorously validated *AFF2* IHC, combined with morphologic evaluation and an appropriate immunohistochemical panel to exclude other differentials, is an effective method to confirm the diagnosis of *DEK::AFF2* sinonasal carcinoma.

Prognosis/clinical behavior

DEK::AFF2 sinonasal carcinoma shows frequent local recurrences or progression (50-55.5%) with occasional lymph node (25.0-29.6%) and distant (17-25.9%) metastases. Tumor-related deaths are found to range from 5.9% to 25%, depending on the reported case series, with variable median follow-up (7-18 months).^{3,5}

CONCLUSION

DEK::AFF2 sinonasal carcinoma is an under-recognized malignant neoplasm. Frequently, it shows papillomatous growth with banal and strikingly monomorphic tumor cells, easily misconstrued as an inverting sinonasal papilloma. In these cases, accurate diagnosis is facilitated by identifying architectural complexity, strikingly monomorphic tumor cells, absence of the typical cellular components of inverting sinonasal papilloma (mucocytes, respiratory-type epithelial cells, and microcysts), and peritumoral neutrophilic infiltrates. An appropriate IHC panel and molecular testing for the *DEK::AFF2* fusion or an *AFF2* IHC targeting the C-terminus as a surrogate will confirm the diagnosis. Awareness of this emerging entity to distinguish from ISP is clinically relevant to prevent delay in surgical management, as it has been shown to behave aggressively with frequent local recurrence, occasional metastasis, and rare tumor-related deaths.

ACKNOWLEDGMENTS

The authors extend their special thanks to Dr. Jen Fan-Hang and Dr. Ying Ju-Kuo for their assistance in confirming the case using a validated *AFF2* IHC stain in Taipei Veterans General Hospital, Department of Pathology and Laboratory Medicine.

STATEMENT OF AUTHORSHIP

All authors certified fulfillment of the ICMJE authorship criteria.

AUTHOR DISCLOSURE

The authors declared no conflict of interest.

FUNDING SOURCE

None.

REFERENCES

1. Rooper LM, Agaimy A, Dickson BC, et al. *DEK-AFF2* carcinoma of the sinonasal region and skull base: detailed clinicopathologic characterization of a distinctive entity. *Am J Surg Pathol*. 2021;45(12):1682-93. PMID: 34049316 DOI: 10.1097/PAS.0000000000001741
2. Kuo YJ, Lewis JS Jr, Truong T, et al. Nuclear expression of *AFF2* C-terminus is a sensitive and specific ancillary marker for *DEK::AFF2* carcinoma of the sinonasal tract. *Mod Pathol*. 2022;35(11):1587-95. PMID: 35701667 DOI: 10.1038/s41379-022-01117-4
3. Rivera JP, Kuo YJ, Hang JF. *DEK::AFF2* carcinoma of the sinonasal tract and skull base: a comprehensive review. *Surg Pathol Clin*. 2024;17:587-97. PMID: 39489551 DOI: 10.1016/j.path.2024.07.008
4. Amin SE, Lewis JS Jr, Bridge JA, et al. *DEK::AFF2* fusion-associated squamous cell carcinoma: a case series with literature review on an emerging and challenging entity. *Head Neck Pathol*. 2024;18(1):86. PMID: 39312022 PMID: PMC11420419 DOI: 10.1007/s12105-024-01690-x
5. Trinquet A, Laé M, Lepine C, et al. Sinonasal squamous cell carcinoma with *DEK::AFF2* rearrangement: an aggressive cancer with bland morphology. *Am J Surg Pathol*. 2024;48(11):1408-16. PMID: 39132684 DOI: 10.1097/PAS.0000000000002281
6. Kuo YJ, Lewis JS Jr, Zhai C, et al. *DEK-AFF2* fusion-associated papillary squamous cell carcinoma of the sinonasal tract: clinicopathologic characterization of seven cases with deceptively bland morphology. *Mod Pathol*. 2021;34(10):1820-30. PMID: 34108636 DOI: 10.1038/s41379-021-00846-2
7. Savari O, Chang JC, Bishop JA, Sakthivel MK, Askin FB, Rekhman N. First report of thoracic carcinoma with *DEK::AFF2* rearrangement: a case report. *J Thorac Oncol*. 2022;17(8):1050-3. PMID: 35773081 PMID: PMC9357138 DOI: 10.1016/j.jtho.2022.05.009

8. Taverna C, Agaimy A, Franchi A. Towards a molecular classification of sinonasal carcinomas: clinical implications and opportunities. *Cancers (Basel)*. 2022;14(6):1463. PMID: 35326613 PMCID: PMC8946109 DOI: 10.3390/cancers14061463
9. Wartenberg M, Hool SL, Marrazzini A, Giger R, Rupp NJ. Differentiated papillary NUT carcinoma: an unexpected, deceptively bland presentation of a sinonasal carcinoma. *Head Neck Pathol*. 2023; 17(3):803-7. PMID: 37118352 PMCID: PMC10513967 DOI: 10.1007/s12105-023-01554-w
10. Yang W, Lee KW, Srivastava RM, et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. *Nat Med*. 2019;25(5):767-75. PMID: 31011208 PMCID: PMC6558662 DOI: 10.1038/s41591-019-0434-2
11. Todorovic E, Truong T, Eskander A, et al. Middle ear and temporal bone nonkeratinizing squamous cell carcinomas with DEK-AFF2 fusion: an emerging entity. *Am J Surg Pathol*. 2020;44(9):1244-50. PMID: 32366754 DOI: 10.1097/PAS.0000000000001498
12. Bishop JA, Gagan J, Paterson C, McLellan D, Sandison A. Nonkeratinizing squamous cell carcinoma of the sinonasal tract with DEK-AFF2: Further Solidifying an Emerging Entity. *Am J Surg Pathol*. 2021;45(5):718-20. PMID: 33002918 DOI: 10.1097/PAS.0000000000001596
13. Tauziede-Espariat A, Chotard G, le Loarer F, et al. A novel LARGE1-AFF2 fusion expanding the molecular alterations associated with the methylation class of neuroepithelial tumors with PATZ1 fusions. *Acta Neuropathol Commun*. 2022;10(1):15. PMID: 35115049 PMCID: PMC8812055 DOI: 10.1186/s40478-022-01317-8
14. Ng JKM, Chow C, Tang CY, Chan AZ, Li JJX, Chan ABW. Prevalence and interpretation of AFF immunostain of DEK::AFF2 fusion-associated papillary squamous cell carcinoma in a retrospective cohort of recurrent sinonasal papillomas. *Virchows Arch*. 2024;484(1):119-25. PMID: 38063896 DOI: 10.1007/s00428-023-03717-0
15. Palsgrove D, Rooper L, Buresh C, Bishop J, Bridge J. AFF2 Immunohistochemistry: a promising surrogate marker for DEK::AFF2 fusion-associated carcinoma. *Lab Invest*. 2023;103(3):s1065. DOI: 10.1016/j.labinv.2023.100092

Disclaimer: This journal is **OPEN ACCESS**, providing immediate access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. As a requirement for submission to the PJP, all authors have accomplished an **AUTHOR FORM**, which declares that the ICMJE criteria for authorship have been met by each author listed, that the article represents original material, has not been published, accepted for publication in other journals, or concurrently submitted to other journals, and that all funding and conflicts of interest have been declared. Consent forms have been secured for the publication of information about patients or cases; otherwise, authors have declared that all means have been exhausted for securing consent.

Publish in the new PJP.
Visit our website:
<https://philippinejournalofpathology.org>